Ficerafusp Alfa采用2000毫克每两周给药方案,在治疗一线复发/转移性HPV阴性头颈部鳞状细胞癌患者时,展现出深度且持久的肿瘤缓解效果。该积极数据为进一步开发给药频率更低的治疗方案提供了有力支持。
Ficerafusp Alfa采用2000毫克每两周给药方案,在治疗一线复发/转移性HPV阴性头颈部鳞状细胞癌患者时,展现出深度且持久的肿瘤缓解效果。该积极数据为进一步开发给药频率更低的治疗方案提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.